Dr. Claire F. Verschraegen – Mesothelioma Doctor – Professor of Medicine, Division of Hematology Oncology

Share This:

University of New Mexico Cancer Center
900 Camino de Salud NE
Albuquerque, New Mexico 87131
Phone: 505.272.4551
Fax: 505.272.2841
Email Address: cverschraegen@salud.unm.edu

Dr. Claire Florence Verschraegen is Professor of Medicine at the Division of Hematology and Oncology and Director of the Translational Therapeutics and Phase I program at the University of New Mexico Cancer Center. She was formerly on faculty at The University of Texas M. D. Anderson Cancer Center in Houston. Her expertise is in the area(s) of the treatment of peritoneal mesothelioma, gynecological cancers, appendiceal cancers, and the study of new anticancer drugs and treatments for these diseases.

Dr. Verschraegen’s education and training is a unique mix of studies, completed in both the states and abroad. She graduated Magna Cum Laude in 1982 from Universite Libre De Bruxelles Medical School. She completed her Internship and Residency (Oncology orientation) at the Universite Libre De Bruxelles Medical School from 1982-1985. From 1988-1991, she completed her Internal Medicine training at the University of Texas. She completed her first Fellowship in 1992 in Baudor, Belgium and her second in Oncology, at the University of Texas at Houston in 1994. She spent three years at the Stehlin Foundation for Cancer Research under the direction of Dr. Beppino Giovanella.

Dr. Verschraegen became board certified in Internal Medicine in 1992/2000 and in Medical Oncology in 1995/2000 from the American Board of Internal Medicine and the Belgian Department of Human Health. Her awards and academic accomplishments are numerous and varied. She received the Occino-Kernkamp Prize from the Belgium Association of University Women and she was a Fullbright Fellow.

Her academic accomplishments include: 10 book chapters, 20 invited papers, and over 80 peer reviewed medical papers. She is a member of the Education Committee of the International Gynecologic Cancer Society (IGCS) and a member of the Scientific Board of the Mesothelioma Applied Research Foundation (MARF). Dr. Verschraegen has also presented at dozens of scientific meetings and she is currently conducting a front-line Alimta/gemcitabine trial for peritoneal mesothelioma patients.

Additionally, for peritoneal patients who have already been treated with Alimtam, Dr. Verschraegen is currently offering several Phase I trials including: Phase I Study of Capecitabine with Cisplatin and Irinotecan in Patients with Advanced Malignancies; Phase I Study of Intravenous TZT-1027 and Gemcitabine, Administered on Day 1 and Day 8 of a Three-Week Course in Patients with Advanced Solid Tumors, and Phase I Study of Flavoperidol in Combination with Gemcitabine and Irinotecan in Patients with Metastatic Cancer. In addition to her current commitments, Dr. Verschraegen also teaches fellows, residents, and students.